

U.S. SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 19B-4(e)

91-12  
FEB 09 2001

Information Required of a Self-Regulatory Organization Listing and Trading a New Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Part I Initial Listing Report

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:  
**Boston Stock Exchange**
2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):  
**Open-End Investment Company**
3. Class of New Derivative Securities Product:  
**Index Fund Shares**
4. Name of Underlying Instrument:  
**iShares NASDAQ Biotechnology Index Fund**
5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:  
**Narrow-Based**
6. Ticker Symbol(s) of New Derivative Securities Product:  
**IBB**
7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:  
**NASDAQ**
8. Settlement Methodology of New Derivative Securities Product:  
**Not Applicable**
9. Position Limits of New Derivative Securities Product (if applicable):



01082103

*only one passed*

PROCESSED

JUN 22 2001

THOMSON  
FINANCIAL

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:  
**Anthony K. Stankiewicz, Esq.**

Title:  
**Corporate Secretary**

Telephone Number:  
**617-235-2006**

Act *Securities Exchange Act of 1934*  
Section *Rule 19b-4(e)*  
File

Public  
Availability *3/5/01*

Manual Signature of Official Responsible for Form:

*Anthony K. Stankiewicz*  
Date:  
**February 7, 2001**